Bli medlem
Bli medlem

Du är här

2015-04-20

aap Implantate AG: aap is granted European patent for silver coating technology

aap Implantate AG / aap is granted European patent for silver coating
technology. Processed and transmitted by NASDAQ OMX Corporate Solutions. The
issuer is solely responsible for the content of this announcement.
aap
Implantate AG (XETRA: AAQ.DE), a developer, manufacturer, and distributor of
innovative trauma products and biomaterials, announced that the European
Patent Office recently granted it an important patent for its silver coating
technology for medical implants.

The European patent (EP 2 437 798 B1) protects both the multifunctional
antibacterial silver coating developed by the company for implants and
relevant medical tools and the method as well as apparatuses for the
production of such a coating. In a next step the European patent will be
nationalized in many key European markets and published in different
languages. After the company was granted a patent for the silver coating
technology last year by the US Patent and Trademark Office (USPTO) and has
this year already been granted further European patents for its LOQTEQ® and
magnesium technology, the patent now granted represents an important further
expansion of the IP portfolio.

The fundamental added value of the silver coating technology lies in the antibacterial property of silver. When using medical implants a biofilm can grow on the surface, in which multi-resistant bacteria and germs are embedded. As a consequence infections can be caused. Silver can prevent the formation of such a biofilm leading to a potential reduction in the number of infections and reoperations. Silver coating technology can thereby make a decisive contribution to improving patient care and reducing healthcare costs. Overall, the silver coating technology is not limited to use solely withaap
Implantate AG's existing portfolio; it can also be used for other orthopaedic implants and surgical instruments. The company plans the submission of the CE approval application for the first silver coated products in the second half of 2015.
Aboutaap
Implantate AG

aap
is a global medical device company headquartered in Berlin, Germany that
develops, manufactures and markets innovative biomaterials and implants that
are used in orthopedic procedures. The Company's products, which include a
full line of plating systems, cannulated screws and bone cement products, are
primarily used in the orthopedic specialty areas of trauma and spine repair.
The Company's products are sold through its direct sales force, distribution
partners and license agreements with OEM partners.aap
's stock is listed in the Prime Standard segment of the Frankfurt Stock
Exchange. For more information, please visit www.aap.de, or download the
Company's investor relations app from the Apple's App Store or Google Play.

Forward-looking statement

This release may contain forward-looking statements based on current
experience, estimates and projections of the management board and currently
available information. They are not guarantees of future performance. Various
known and unknown risks, uncertainties and other factors could lead to
material differences between the actual future results, financial situation,
development or performance of the company and the estimates given here. Many
factors could cause the actual results, performance or achievements of aap to
be materially different from those that may be expressed or implied by such
statements. These factors include those discussed inaap
's public reports. Forward-looking statements therefore speak only as of the
date they are made.aap
does not assume any obligation to update the forward-looking statements
contained in this release or to conform them to future events or
developments.

For inquiries please contact:aap
Implantate AG, Fabian Franke, Investor Relations, Lorenzweg 5, 12099 Berlin,
Germany

Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, e-mail: f.franke@aap.de

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: aap Implantate AG via Globenewswire

HUG#1912170

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.